Preoperative serum TMAO level is a new prognostic marker for colorectal cancer
| Autor: | Wei Wang, Heng Liu, Shuding Hu, Xiaomei Liu, Lei Liu, Yinxu Zhang, Ying Wang, Caijun Yuan |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Adult
Male 0301 basic medicine Oncology medicine.medical_specialty Colorectal cancer Lymphovascular invasion Clinical Biochemistry Disease-Free Survival Metastasis Methylamines Young Adult 03 medical and health sciences 0302 clinical medicine Internal medicine Drug Discovery Biomarkers Tumor Humans Medicine Prognostic biomarker In patient Tumor location Aged business.industry Biochemistry (medical) High serum Middle Aged medicine.disease Chemotherapy regimen 030104 developmental biology 030220 oncology & carcinogenesis Preoperative Period Female Colorectal Neoplasms business |
| Zdroj: | Biomarkers in Medicine. 11:443-447 |
| ISSN: | 1752-0371 1752-0363 |
| DOI: | 10.2217/bmm-2016-0262 |
| Popis: | Aim: This study is aimed to determine whether trimethylamine-N-oxide (TMAO) is a predictor of prognosis of patients with colorectal cancer. Methods: Pretreatment TMAO serum levels were determined in 108 patients with colorectal cancer and 30 healthy controls. Results: Median serum TMAO level was significantly higher in colorectal cancer patients than in healthy controls (p < 0.01). No correlation was observed between the disease-free survival and the type of chemotherapy regimen used, tumor location or lymphovascular invasion. Patients with high serum TMAO level had significantly shorter disease-free survival than patients with low serum TMAO level. Multivariate analysis showed that serum TMAO level and distant metastases were independent prognostic factors. Conclusion: Pretreatment serum TMAO level is identified as a new independent prognostic biomarker in patients with colorectal cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|